MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 1.55 and traded as low as GBX 1.26. MaxCyte shares last traded at GBX 1.28, with a volume of 1,389,190 shares changing hands.
MaxCyte Price Performance
The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The business has a 50-day moving average of GBX 1.55 and a 200 day moving average of GBX 1.66. The firm has a market capitalization of £1.37 million, a PE ratio of -0.03 and a beta of 1.13.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.
Featured Stories
- Five stocks we like better than MaxCyte
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
